ABSTRACT
Objective: To correlate the immunoexpression of epithelial-mesenchymal transition
markers, vimentin and E-cadherin (E-CAD), and putative markers, podoplanin (PDPN)
and osteopontin (OTPN), with the expression of interleukin (IL-6), P53, and Ki-67,
and with clinical and histological parameters of oral epithelial dysplasia (ED). Study
design: Immunohistochemical reactions were performed in 61 cases of leukoplakia with
ED, graded as low-risk (LRED=38) and high-risk (HRED=23) for malignant transformation.
Odds ratios (OR) and 95% confidence intervals (CI) were calculated using logistic
regression analysis. Results: HRED was more frequently observed in non-homogeneous
leukoplakia (OR:7.66; CI:1.43–41.04), lesions on the tongue/floor of the mouth (OR:3.37;
95% CI:1.14–9.94), and intense PDPN expression (OR:9.17; CI:1.0–83.77). HRED exhibited
higher Ki-67 expression than LRED (P=0.013). Non-continuous PDPN was more likely to exhibit extensive loss of E-CAD than
continuous PDPN expression (OR:5.81; CI:1.18–28.55). Intense OTPN was more likely
to exhibit intense IL-6 than mild/moderate OTPN expression (OR: 8.06, 95% CI: 1.33–48.85).
P53 expression was higher in the intense IL-6 group than in the mild/moderate expression
group (P=0.021). Conclusions: Our data support the potential of PDPN as a biomarker for malignant
transformation owing to its association with HRED and loss of E-CAD expression. Additionally,
we demonstrated a possible shared regulatory mechanism between IL-6 and OTPN expression.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
Accepted:
March 6,
2023
Received in revised form:
February 21,
2023
Received:
August 29,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2023 Elsevier Inc. All rights reserved.